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ABSTRACT 
The poor bioavailability of drugs has been identified as the single most important challenge in oral drug delivery. 
Prominent among the factors responsible for this are the oxidative metabolic activity of the intestinal and hepatic 
cytochrome P450 enzyme family. Naringin and naringenin which are the major phytochemical component of 
grapefruit juice, a well-known cytochrome P450 3A4 inhibitor and flavone glycoside, is antioxidant in nature and 
occurs naturally in the pericarp of citrus fruit, and particularly of grapefruit (Citrus paradisii) where it is the 
predominant flavonoid found and is responsible for the bitter taste associated with the fruit. CYP3A4 which is a 
class of CYP – 450 (microsomal enzyme) is responsible for the oxidative metabolic reaction of various substrates 
which decreases the bioavailability of drug.  
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INTRODUCTION 
The ability of administered drug to elicit the desired 
pharmacologic response and reverse or modify a disease 
condition is the ultimate goal of drug therapy. Serum 
drug concentration determines the availability of drug 
molecules at their receptor site. Thus, the rate and extent 
of drug absorption (bioavailability) from the GIT is an 
important factor that determines the plasma 
concentrations of orally administered drug. With a 
general preference for the oral route of drug 
administration, first-pass drug metabolism due to 
oxidation has become one of the most singularly 
important considerations in drug delivery [1].  
With regard to CYP3A4 substrates, the abundance of 
CYP3A4 in the intestines and the liver makes the oral 
bioavailability of its substrates extremely poor [2].   
Thus, successful inhibition of their pre-systemic activity 
presents the potential for improved oral bioavailability 
of drugs [3]. In addition, the required oral dosage may be 
greatly reduced, thus enhancing patient convenience and 
compliance. Studies in this area have shown that certain 
chemical compounds including therapeutic agents, 
herbal extracts and phytochemicals are capable of 
inhibiting the metabolic activity of CYP3A4 [4].  
Hepatic enzymes shows Phase 1 Reaction for 
biotransformation of First pass metabolism i.e 
Oxidation. Herbal extract which may be antioxidant 
(Naringin- active Flavanoid of grape fruit) may cause 
reversible or irreversible inhibition of CYP enzymes 
and thus prevent biotransformation of substrates. In 
reversible inhibition, a preferentially lipophilic 
compound binds tightly within the active site of the 
enzyme. This prevents binding of other substrate 
molecules to active hydrophobic regions on the CYP 
apoprotein or oxygen activationby CYP heme, both 
actions resulting in transient although sometimes potent 
inhibition of enzyme activity. 
 
Figure 1: Schematic illustrating the pre-systemic fate of 
drug administered via the oral route  
 
MECHANISMS OF CYP INHIBITION 
[5]
: 
Hepatic enzymes shows Phase 1 Reaction for 
biotransformation of First pass metabolism i.e 
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Oxidation. Herbal extract which may be antioxidant 
(Naringin- active Flavanoid of grape fruit) may cause 
reversible or irreversible inhibition of CYP enzymes 
and thus prevent biotransformation of substrates. In 
reversible inhibition, a preferentially lipophilic 
compound binds tightly within the active site of the 
enzyme. This prevents binding of other substrate 
molecules to active hydrophobic regions on the CYP 
apoprotein or oxygen activationby CYP heme, both 
actions resulting in transient although sometimes potent 
inhibition of enzyme activity. 
 
GRAPE FRUIT 
The grapefruit (Citrus paradisi) is a subtropical citrus 
tree known for its sour to semi-sweet fruit [6].  Grapefruit 
contains a number of polyphenolic compounds, 
including the flavanone naringin, alongside the two 
furanocoumarins bergamottin and dihydroxy 
bergamottin. These inhibit the drug-metabolizing 
enzyme isoform CYP3A4 predominantly in the small 
intestine, but at higher doses also inhibit hepatic 
CYP3A4. It is via inhibition of oxidation of this enzyme 
that grapefruit increases the effects of a variety of drugs 
by increasing their bioavailability [7-12] 
 
Figure 2: Role of CYP Enzymes in Hepatic Drug 
Metabolism 
 
 
Figure 3   - Image of Grape fruit 
 
NARINGIN- AN ACTIVE FLAVONOID OF 
GRAPE FRUIT 
[13, 14]
: 
Naringin is the major flavonoid glycoside in grapefruit 
and gives grapefruit juice its bitter taste. It is 
metabolized to the flavanone naringenin in humans. 
Both naringin and hesperidins, which are the aglycones 
of naringin and hesperidin, occur naturally in citrus 
fruits. 
Naringin exerts a variety of pharmacological effects 
such as antioxidant activity, blood lipid lowering, 
anticancer activity, and inhibition of selectdrug 
metabolizing cytochrome P450 enzymes, including 
CYP3A4 and CYP1A2, which may result in drug - drug 
interactions in vivo. Ingestion of naringin and related 
flavonoids can also affect the intestinal absorption of 
certain drugs, leading to either an increase or decrease 
in circulating drug levels. 
 
Structural formula of Naringin 
 
MATERIAL AND METHOD: 
The material required for the formulation of double 
layer tablet requires following material: 
Lactose monohydrate, Calcium carbonate (CDH, New 
Delhi), Sodium Starch glycolate (CDH, New Delhi), 
Micro crystalline cellulose (CDH, New Delhi), Maize 
Starch (CDH, New Delhi), Poly vinyl pyrollidon k30 
(CDH, New Delhi), Chitosan (Balaji drugs), Eudragit L- 
100 (Balaji drugs), Bio extract of Grape fruit (Naringin), 
Drug. 
1. COLLECTION OF GRAPEFRUIT PEELS FOR 
EXTRACTION OF                NARINGIN: 
The grapefruit peels were collected from local market of 
Dehradun, Uttarakhand and it was used for the 
extraction of naringin (flavonoid). 
 
2. Extraction of naringin from grapefruit peels 15-18]: 
Journal of Applied Pharmaceutical Research ISSN No. 2348 – 0335 www.japtronline.com 
 
 
 
July – September 2014 Volume 2                                        Issue 3  22 
 
The extraction of Naringin, the principal flavonoid of  
Grapefruit rind was done by Soxhlet Extraction method.  
In this method fresh samples of grapefruit peel were 
taken. 40.0 gram was grounded in a blender with 100 ml 
of Ethyl alcohol for 1 minute. The mixture was than 
filtered and filtrates and residue was divided. The 
residue was air dried to remove alcohol. The portion of 
filtrate was placed in a Solvent Extraction flask with 50 
ml of ethanol and extraction was carried out for 3 hours. 
The filtrate was then evaporated at 50 °C, dried at 50 °C 
and stored at room temperature. 
Fig 4: Extraction of naringin from grapefruit peel. 
 
CONFIRMATORY TEST OF NARINGIN: 
Test Inference Result 
5mg of naringin is 
dissolved in 10ml 
of ethyl alcohol, 1-
2 drop of ferric 
chloride solution 
are added. 
Brown colour 
Brown 
colour is 
present. 
5mg naringin is 
dissolved in 5ml of 
sodium hydroxide 
solution. 
Orange yellow 
colour 
Orange 
yellow 
colour is 
present. 
 
IN – VITRO DETERMINATION OF 
ANTIOXIDANT ACTIVITY OF NARINGIN:  
The CYP3A4 shows oxidative metabolism of drug and 
the naringin acts as antioxidant which inhibits the 
oxidative metabolism causes by CYP3A4. The 
determination of antioxidant activity of naringin is done 
by using DPPH (2, 2- diphenyl-1- picrylhydrazyl). 
QUALITATIVE ANALYSIS: In order to detect the 
antioxidant activity, a method based on reduction of 2, 
2- diphenyl – 1- picrylhydrazyl (DPPH) can be carried 
out. DPPH is a free radical stable at room temperature, 
which produces a violet solution in methanol. When the 
free radical reacts to an antioxidant, its free radical 
property is lost due to chain breakage and its color 
changes to light yellow. 
The procedure in brief is – extract resolved in solvent is 
spotted on the silica- gel TLC plates and the 
chromatogram is developed.  The methanolic solution of 
DPPH (2mg/ml) is prepared. After spoting the extract 
(naringin) on TLC plates, the plates were immersed in 
DPPH methanolic solution. The plates were removed 
allowed for air drying after drying the Vanillin/H2SO4 
reagent is sprayed on the plates as visualizing agent. 
After sprying the plates were observed under UV-
365.The orange Yellow colour indicates presence of 
Flavonoid (naringin). 
 
Figure 5: Identification of antioxidant activity of 
antioxidant (Naringin) on TLC plates 
 
Scanning of Terbinafine hydrochloride by U.V-
visible Spectroscopy: Scanning of Terbinafine 
hydrochloride was determined by making dilution in 
methanol and observing under U.V- Visible 
Spectrophotometry in the range 200-400 nm.  
It was found out 233 nm. 
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Standard curve of Terbinafine hydrochloride: the 
standard curve of terbinafine as obtained by making 
dilutions in ethanol and then observing under U.V 
Spectroscopy. 
Scanning of Naringin by U.V-Visible Spectroscopy: 
The scanning of naringin was determined by making 
dilution in ethanol and observing under U.V- Visible 
Spectrophotometry in the range 200-400 nm and was 
found 221 nm 
 
 
 
UV scanning report and standard curve of Terbinafine 
hydrochloride and UV scanning report of naringin  
 
METHADOLOGY: 
Formula for the formulation of inner layer 
(naringin): 
For the formulation of inner layer the ingredients are 
Naringin (100 mg), Lactose monohydrate (300 mg), 
Chitosan (100 mg), Eudragit L-100 (150 mg) and Poly 
Vinyl Pyrollidon K30 (16 % w/v). 
Formulation Methodology: Wet Granulation 
Method 
Reason for the formulation of double layer tablets: 
Terbinafine hydrochloride has its absorption window in 
stomach, so it is necessary to deliver the drug in the 
stomach, whereas the naringin has its absorption 
window in small intestine and it is unstable in acidic 
condition. Hence it is necessary to coat the naringin 
tablets with enteric coating polymers and deliver it into 
small intestine whereas the terbinafine hydrochloride 
tablets will release into stomach only. 
All the ingredients were weighed accurately and 
blended well. Binder solution was prepared in distilled 
water and added to form granules. Granules were 
allowed to air dry so that the moisture gets evaporated. 
Granules were allowed to punch in double layer tablets. 
 
Table 1: formula used for formulation of outer layer 
(terbinafine hydrochloride): 
 
EVALUATION PARAMETERS: 
Flow properties of granules: 
A) Angle of Repose: 
The maximum angle possible between the surface of a 
pile of powder and the horizontal plane Poorly flowing 
0
1
2
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A
b
so
rb
an
ce
Conc(µg/ml)
Standard curve of terbinafine hydrochloride 
Sr. 
No 
Ingredients 
Formulation 
F1 F2 F3 F4 
1. 
Drug(Terbinafine 
Hydrochloride) (mg) 
100 100 100 100 
2. 
Calcium Carbonate 
(mg) 
150 150 150 150 
3. 
Micro Crystalline 
Cellulose (mg) 
100 150 200 - 
4. 
Sodium Starch 
Glycolate (mg) 
- - - 300 
5. 
Lactose 
monohydrate (mg) 
300 300 300 300 
6. Tragacanth (w/v) - 13% - - 
7. 
Poly Vinyl 
Pyrollidone k30 
(w/v) 
12% - - 
15
% 
8. 
Maize Starch paste 
(w/v) 
- - 
13
% 
- 
9. Magnesium Stearate q.s q.s q.s q.s 
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powders or granulations present many difficulties to the 
pharmaceutical industry.  
B) Bulk Density: 
Bulk density is defined as the ratio of mass of the 
powder and its bulk volume 
C) Weight variation test:  
20 tablets were weighed and the average weight was 
calculated. The individual weight was compared with 
the average weight. The tablet pass the test if not more 
than two tablets are outside the percentage limit and if 
no tablet differs by, more than two tablets the 
percentage limit. The following percent deviation in 
weight variation is allowed according to U.S.P. 
Formul
ation 
Parameters 
Angle 
of 
repose 
Bulk 
density 
(g/ml) 
Tapped 
density  
(g/ml) 
Hausner
’s  
Ratio 
F1 26°56´ 0.519 0.523 1.007 
F2 27° 03´ 0.522 0.527 1.0095 
F3 26°21´ 0.60 0.66 1.1 
F4 25°33´ 0.503 0.514 1.021 
Table 2: Flow properties of Terbinafine hydrochloride 
granules 
 
Hardness test: 
Hardness indicates the ability of tablets to withstand 
mechanical shocks while handling. The hardness of 
tablet was determined by using Monsanto Hardness 
Tester. It was expressed in kg/cm2.   
 
Fig- 5 hardness parameter of different formulations 
Disintegration test: 
Disintegration is defined as the process of breakdown of 
tablet into fragments. The disintegration time for 
uncoated tablet is 5 min. Since we are using two layers 
hence we have to test both layer i.e uncoated outer layer 
(Terbinafine hydrochloride) and coated inner layer 
(Naringin). 
In- vitro dissolution studies: 
Double layer tablets were subjected to in – vitro 
dissolution studies in simulated gastric and intestinal 
fluids to assess their ability in providing the desired 
drug delivery. The temperature was maintained at 37 ± 
2 o C. 
 
FORMU
LATION 
 
DISINTEGRATION TIME( min) 
(Terbinafine hydrochloride) 
F1 4 min 
F2 4.10 min 
F3 5 min 
F4 4.3 min 
 
Table 3: Disintegration test of Terbinafine 
hydrochloride tablet: 
 
 S.n 
Formulation and 
polymer used 
Weight of 
tablet after 
dip 
Disintegrati
on 
Time 
1. F1 
(Eudragit L-100 
-12%) 
0.254 mg 45 min 
2. 0.260mg 1.20 hr 
3. 0.305mg 2 hr 
4. F2 
(Eudragit S – 
100) 
0.245 40 min 
5. 0.251 1.15 min 
6. 0.268 1.45 min 
7. F3 
(Ethyl Cellulose- 
10%) 
0.233 1 hr 
8. 0.246 1.35 min 
9. 0.263 2. 20 min 
10. F4 
(Eudragit L- 100 
-15%) 
0.242 1 hr 
11. 0.271 1.30 hr 
12. 0.304 2.20 hr 
 
Table 4: Disintegration test of Naringin tablet: 
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Release kinetics of different formulations after in-
vitro release study 
 
 
 
Fig- drug compatibility study through FTIR 
 
 
CONCLUSION: 
The various biochemicals, anatomical and physiological 
barriers to oral drug absorption and bioavailability have 
received considerable attention in drug delivery studies. 
The various approaches aimed at enhancing oral drug 
delivery were presented in this article. Being 
responsible for the metabolism and pre-systemic 
metabolism of greater than 50% of all administered 
drugs, the CYP enzyme family was identified as the 
single most important factor influencing oral drug 
delivery for enhanced bioavailability. The study 
confirmed that the component flavonoids, the major 
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phytochemicals found in grapefruit juice are responsible 
for grapefruit-drug interactions.  
The present work involves the formulation and 
evaluation of Naringin double layer tablet as 
antioxidant. The method used was wet granulation and 
various parameters were evaluated. In – Vitro studies 
showed that the formulation F4 was the optimised batch 
as its N value of Korsmeyer and Peppas is maximum 
and favours zero order release mechanism and also 
covers the specification required for formulation. All the 
evaluation parameter including FTIR have been studied. 
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